HeraMED Ltd. (DE:1I4)
FRANKFURT:1I4
1I4 Stock Chart & Stats
€0.02
<€0.01(10.00%)
At close: 4:00 PM EST
€0.02
<€0.01(10.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)152.85K
Market Cap
€30.59M
Enterprise Value€24.37M
Total Cash (Recent Filing)€914.65K
Total Debt (Recent Filing)€282.39K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,116,287,200
10 Day Avg. Volume114,978
30 Day Avg. Volume152,848
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA sustained ~60% gross margin indicates the core product/service mix can earn healthy unit economics. Over 2–6 months this supports scalability: if operating expenses are controlled, the company can convert revenue growth into profits more easily than low-margin peers, improving long-term viability.
Deleveraged Balance SheetZero reported debt materially reduces near-term solvency risk and interest obligations, giving management flexibility to fund growth or absorb shocks. While equity is small, the lack of leverage preserves optionality for refinancing or strategic investments without immediate debt service constraints.
Focused Digital Health Business ModelA focused software-plus-connected-device model in women's health targets a defined, recurring-care vertical. This structure supports recurring service relationships, potential subscription or service revenue, and product-led scale, aligning the company with durable structural demand for remote monitoring and clinician workflows.
Bears Say
Persistent Negative Cash FlowContinued annual negative operating and free cash flow reflects structural cash burn; the business needs external funding to sustain operations. Over months this raises financing risk, limits reinvestment in product and go-to-market, and can force dilution or cutbacks if cash runway is constrained.
Consistent Losses And Negative MarginsDespite improved gross margins, the company has failed to achieve operating profitability, implying structural cost or scale issues. Persistent negative net margins indicate that current revenue levels do not cover fixed and operating costs, challenging long-term self-sustainability without major margin or revenue improvements.
Revenue Volatility And Recent ContractionVolatile and declining revenue undermines predictable unit economics and delays operating leverage. Over a multi-month horizon, inconsistent top-line performance raises execution risk, complicates budgeting and growth investment decisions, and makes it harder to demonstrate sustainable demand to partners or investors.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is €30.59M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 155 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,116,287,200 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in DE:1I4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:1I4 Sentiment 62%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-417.72%
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.